Abstract 216P
Background
Wilms tumor (WT) is a rare kidney cancer, but it is the most common malignant tumor of the kidneys of children. Although radical nephroectomy has been viewed as the gold standard surgery in Wilms tumor management for many years, partial nephrectomy has gained a lot of attention recently. So we conducted this study to compare the long term overall survival between those two different surgical techniques.
Methods
Using SEER database, we extracted the data of 636 patients with WT from 2000 to 2006. There were 55 (8.6%) patients underwent partial nephrectomy, while 581 (91.4%) of them underwent radical nephrectomy. Patients’ demographics were assessed.
Results
Our study showed that there is NO significant difference in Long-Term overall survival between partial nephrectomy and radical nephrectomy, where overall 10-year relative survival rates were 92.6% and 88.1%, respectively (p value =0.240). Subgroup analysis revealed NO significant difference in overall survival Except in patients with different age groups as seen in the table (p value <0.0001) but this could have been caused by the fact that few patients were recorded.
Table: 216P
Variables | Survival of Patients | p value | |
---|---|---|---|
Partial nephroectomy | Radical nephroectomy | ||
Sex Male Female | 96 % 89.7 % | 87.9 % 88.3 % | 0.821 |
Age 0- 9 10-19 20-39 40-59 60-79 | 91.5% 100%** 100%** 100%** 100%** | 89.9% 71.8% 36.4% 100% 66.7% | <0.0001*** |
Race White | 91% 100% _* % _* % | 88.8% 86.1% 88.9% 83.3% | 0.574 |
Black American Indian/Alaska Asian/pacific Islander | |||
Laterality Right left Bilateral | 89.9% 92.9% 95% | 90.1% 85.8% 92% | 0.175 |
Highly significant P-value ≤ 0.001.
**few no. of cases _.
*no recorded patients.
Conclusions
There is NO significant difference in overall 10-year survival between partial nephrectomy and radical nephrectomy. So, we recommend the application of partial nephrectomy in the appropriate patients to preserve as much kidney tissue and function as possible especially in bilateral WT. Further studies should be conducted on larger number of patients and they should study the efficacy of chemotherapy in patients undergoing partial nephrectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Mira Mohamed Mostafa.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract